Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
复制标题
DOI：
10.1016/j.drugpo.2021.103537
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Sherman SG
中科院分区：
文献类型：
--
作者：
Saloner B;Krawczyk N;Solomon K;Allen ST;Morris M;Haney K;Sherman SG
2019冠状病毒病大流行期间，药物过量激增，凸显了扩大和获得物质使用障碍（SUD）治疗的需求。对于在大流行期间接受治疗的患者的经历，人们所知相对较少。从2020年8月到2021年1月，我们与9个州和哥伦比亚特区的21个减少伤害和药物治疗项目合作。项目组向客户分发研究招募卡。客户通过拨打研究热线并提供唯一的研究识别号码来回应调查。我们的调查包括有关COVID-19大流行之前和之后使用SUD治疗的详细问题。我们确定了个人接受治疗的环境，对于那些接受阿片类药物使用障碍治疗的人，我们检查了阿片类药物使用障碍的药物使用情况。个人还报告了他们是否接受了远程保健治疗和与大流行病有关的治疗变化（例如，更多带回家的美沙酮）。我们计算了COVID-19前后差异的p值。我们访问了587名人士，其中316名（53. 8%）在COVID-19疫情之前及期间均接受药物治疗。接受治疗的个人报告说，自大流行开始以来，面对面服务的使用大幅减少，包括团体咨询会议减少27个百分点（p<.001），互助团体参与减少28个百分点（p<.001）。相比之下，个人报告接受过量教育增加了21个百分点（p<.001）。大多数接受阿片类药物使用障碍药物治疗的人报告服用美沙酮，并且治疗的连续性很高（86.1%在COVID前接受美沙酮，87.1%在COVID后接受美沙酮，p= 0.71）。几乎所有人都报告说，他们利用了新的政策变化，如通过视频/电话咨询，增加带回家的药物，或减少尿液药物筛查。总体而言，受访者对他们的治疗和远程保健适应措施（例如，80.2%的人报告“我能够得到我需要的所有治疗”）。在联邦公共卫生紧急情况下作出的治疗豁免似乎在大流行的最初几个月里持续获得了治疗。由于这些变化将在官方宣布公共卫生紧急状态后到期，因此需要采取进一步行动以满足持续的需求。
Drug overdoses surged during the COVID-19 pandemic, underscoring the need for expanded and accessible substance use disorder (SUD) treatment. Relatively little is known about the experiences of patients receiving treatment during the pandemic. We worked with 21 harm reduction and drug treatment programs in nine states and the District of Columbia from August 2020 to January 2021. Programs distributed study recruitment cards to clients. Clients responded to the survey by calling a study hotline and providing a unique study identification number. Our survey included detailed questions about use of SUD treatment prior to and since the COVID-19 pandemic. We identified settings where individuals received treatment and, for those treated for opioid use disorder, we examined use of medications for opioid use disorder. Individuals also reported whether they had received telehealth treatment and pandemic related treatment changes (e.g., more take-home methadone). We calculated p-values for differences pre and since COVID-19. We interviewed 587 individuals of whom 316 (53.8%) were in drug treatment both before and during the COVID-19 pandemic. Individuals in treatment reported substantial reductions in in-person service use since the start of the pandemic, including a 27 percentage point reduction (p<.001) in group counseling sessions and 28 percentage point reduction in mutual aid group participation (p<.001). By contrast, individuals reported a 21 percentage point increase in receipt of overdose education (p<.001). Most people receiving medications for opioid use disorder reported taking methadone and had high continuity of treatment (86.1% received methadone pre-COVID and 87.1% since-COVID, p=.71). Almost all reported taking advantage of new policy changes such as counseling by video/phone, increased take-home medication, or fewer urine drug screens. Overall, respondents reported relatively high satisfaction with their treatment and with telehealth adaptations (e.g., 80.2% reported “I'm able to get all the treatment that I need”). Accommodations to treatment made under the federal public health emergency appear to have sustained access to treatment in the early months of the pandemic. Since these changes are set to expire after the official public health emergency declaration, further action is needed to meet the ongoing need.
登录
查看更多内容
DOI：
10.1097/qai.0000000000001959
发表时间：
2019-04-15
影响因子：
3.6
作者：
Sherman, Susan G.;Park, Ju Nyeong;Footer, Katherine H. A.
通讯作者：
Footer, Katherine H. A.
影响因子：
4.2
作者：
Jacka BP;Janssen T;Garner BR;Yermash J;Yap KR;Ball EL;Hartzler B;Becker SJ
通讯作者：
Becker SJ
在19009年大流行期间，处方阿片类镇痛药和丁丙诺啡的阿片类药物使用障碍。
影响因子：
13.8
作者：
Currie JM;Schnell MK;Schwandt H;Zhang J
通讯作者：
Zhang J
DOI：
10.1016/j.drugpo.2021.103140
发表时间：
2021-06
期刊：
The International journal on drug policy
影响因子：
--
作者：
Krawczyk N;Bunting AM;Frank D;Arshonsky J;Gu Y;Friedman SR;Bragg MA
通讯作者：
Bragg MA
影响因子：
3.8
作者：
Haque, Saira Naim
通讯作者：
Haque, Saira Naim